Prognostic Factors in a Large Nationwide Cohort of Histologically Confirmed Primary and Secondary Angiosarcomas.
angiosarcoma
clinical subtype
epidemiology
pathology review
prognostic factors
Journal
Cancers
ISSN: 2072-6694
Titre abrégé: Cancers (Basel)
Pays: Switzerland
ID NLM: 101526829
Informations de publication
Date de publication:
12 Nov 2019
12 Nov 2019
Historique:
received:
16
10
2019
revised:
07
11
2019
accepted:
09
11
2019
entrez:
16
11
2019
pubmed:
16
11
2019
medline:
16
11
2019
Statut:
epublish
Résumé
Angiosarcoma (AS) is a rare sarcoma of endothelial origin, arising spontaneously (primary AS) or after external damage such as radiation therapy or UV exposure (secondary AS). To date, reliable assessment of prognostic factors has proven difficult, due to disease rarity and heterogeneity of study cohorts. Although large registries provide relatively large AS patient series, these cases often lack histological confirmation. This study aimed to analyze AS prognostic factors in a large nationwide cohort of histologically confirmed cases, established through linkage of clinical data from the Netherlands Cancer Registry and pathology data from the Dutch pathology registry (PALGA). All cases were reviewed by an expert pathologist, showing a 16% discordance rate. Multivariable Cox regression survival analysis among 479 confirmed AS patients revealed remarkably poorer overall survival (OS) for primary AS compared to secondary AS (7 vs 21 months, Hazard ratio (HR) = 1.5; 95% confidence interval (CI) = 1.2-1.9). Age above 65 years, male gender, and no surgical treatment also significantly correlated to worse OS. Overall, OS was relatively poor, with a median of 13 months (95% CI = 10-16 months) and 22% five-year survival rate. With this study, we illustrate AS heterogeneity in clinical behavior and show for the first time better survival for secondary AS compared to primary AS.
Identifiants
pubmed: 31726650
pii: cancers11111780
doi: 10.3390/cancers11111780
pmc: PMC6896046
pii:
doi:
Types de publication
Journal Article
Langues
eng
Subventions
Organisme : Honderdduizend Keer een Tientje (HDKT)
ID : -
Références
PLoS One. 2018 Apr 5;13(4):e0193330
pubmed: 29621244
Mod Pathol. 2014 Jan;27 Suppl 1:S30-8
pubmed: 24384851
Am J Clin Oncol. 2014 Oct;37(5):473-9
pubmed: 23428947
J Cutan Pathol. 2011 Dec;38(12):961-6
pubmed: 22050093
J Surg Oncol. 2016 Oct;114(5):557-563
pubmed: 27378102
Cell Oncol. 2007;29(1):19-24
pubmed: 17429138
Head Neck Pathol. 2019 Sep;13(3):378-385
pubmed: 30357539
Ann Surg Oncol. 2008 Mar;15(3):683-90
pubmed: 18183467
Ann Diagn Pathol. 2011 Apr;15(2):93-7
pubmed: 21190880
BMC Cancer. 2017 Apr 27;17(1):295
pubmed: 28449661
Cancer. 2019 Sep 1;125(17):2926-2934
pubmed: 31090929
Lancet Oncol. 2010 Oct;11(10):983-91
pubmed: 20537949
Clin Oncol (R Coll Radiol). 2019 Apr;31(4):232-241
pubmed: 30718086
Ann Surg. 2010 Jun;251(6):1098-106
pubmed: 20485141
Ann Oncol. 2012 Sep;23(9):2442-9
pubmed: 22331640
Ann Oncol. 2007 Dec;18(12):2030-6
pubmed: 17974557
Ann Oncol. 2017 Nov 1;28(11):2852-2859
pubmed: 29117335
Oncol Lett. 2017 Nov;14(5):5370-5378
pubmed: 29113171
Br J Cancer. 2011 Feb 15;104(4):693-9
pubmed: 21266980
Am J Clin Oncol. 2013 Apr;36(2):174-80
pubmed: 22314000
Eur J Cancer. 2013 Jan;49(2):369-76
pubmed: 22967726
Histopathology. 2006 Jan;48(1):42-50
pubmed: 16359536